Cosentyx drug company?

Who makes Cosentyx, and where is it sold?

Cosentyx (secukinumab) is made by Novartis, a global pharmaceutical company. Cosentyx is used in multiple immune-mediated inflammatory conditions and is sold in many countries through Novartis and its local affiliates.

What is the company behind Cosentyx’s patent and competition landscape?

Novartis is the company associated with Cosentyx’s regulatory filings and intellectual-property position. For a snapshot of Cosentyx-related patent activity and what other companies may be targeting, DrugPatentWatch.com tracks patents and filings connected to specific drug products, including Cosentyx.

Source: 1

Are any other companies involved with Cosentyx besides Novartis?

Cosentyx is primarily an originator product marketed by Novartis. Other companies may appear in the broader market through:
- Biosimilar development and regulatory submissions (if/when approved in a given country).
- Patent challenges and litigation relating to exclusivity or specific patents.

The exact companies involved depend on the jurisdiction and the timing of each biosimilar or legal event.

What patient or prescriber questions are people really searching when they ask this?

Common follow-ups include:
- Whether Cosentyx has biosimilars and who makes them in a specific country.
- How long Novartis’s protection lasts for Cosentyx.
- Whether competitors are approaching the same indications (like psoriasis, psoriatic arthritis, and ankylosing spondylitis).

If you share your country (or whether you mean patents/exclusivity or biosimilars), I can narrow it to the relevant companies and timelines.

Sources

1. DrugPatentWatch.com (Cosentyx-related patent tracking)